PYXS Pyxis Oncology
- 1.760
- +0.060+3.53%
- 1.760
- 0.0000.00%
Pyxis Oncology News
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $8
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $5
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology Analyst Ratings
RBC Cuts Price Target on Pyxis Oncology to $8 From $10, Keeps Outperform, Speculative Risk
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $7 to $10
Pyxis Oncology Is Maintained at Outperform by RBC Capital
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $10
Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Pyxis Oncology Analyst Ratings
William Blair Initiates Pyxis Oncology(PYXS.US) With Hold Rating
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $10
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology Initiated at Overweight by Stephens & Co.
Stephens Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $13
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Leerink Partners Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12
No Data